TREM2 is a receptor found on the surface of macrophages and their brain-resident cousins, microglia, that acts as a sensor for damage and disease. In Alzheimer’s disease, TREM2 helps microglia detect amyloid plaques and clear debris, and a single mutation in the TREM2 gene roughly triples a person’s risk of developing the disease. In most solid cancers, though, TREM2 does something closer to the opposite: it sits on tumor-associated macrophages and helps tumors hide from the immune system. This dual identity makes TREM2 one of the more unusual therapeutic targets in medicine, because the strategies that could treat Alzheimer’s and the strategies that could treat cancer pull the receptor in opposite directions.
How TREM2 Sends Its Signals
TREM2 sits on the outside of myeloid immune cells, where it detects lipids and other molecules that accumulate around damaged or dying tissue. It recognizes a broad range of fats found on the surface of injured neurons and embedded in amyloid plaques, including phosphatidylcholine and sphingomyelin.1Cell. TREM2 Sustains Microglial Response to Amyloid Plaques and Damaged Neurons in Alzheimer’s Disease When TREM2 locks onto one of these ligands, it partners with an adaptor protein called DAP12 inside the cell membrane. DAP12 then recruits the enzyme SYK, which kicks off a cascade of downstream signals, including the PI3K-AKT and mTOR pathways, that ramp up the cell’s energy production, phagocytic activity, and survival.2Cell. Microglial SYK-mediated signaling sustains the mechanism of Alzheimer’s disease-associated microglia In practical terms, TREM2 flips these immune cells from a quiet resting state into an active one equipped to eat cellular debris, process lipids, and mount an inflammatory or anti-inflammatory response depending on context.
One additional wrinkle: TREM2 does not stay permanently anchored on the cell surface. Enzymes called ADAM proteases clip its outer portion, releasing a fragment known as soluble TREM2, or sTREM2, into the surrounding fluid.3PubMed Central. TREM2 ectodomain and its soluble form in Alzheimer’s disease This shedding reduces the amount of functional TREM2 on the cell and also generates a molecule that can be measured in cerebrospinal fluid, which has become relevant for tracking neuroinflammation.
A Rare Mutation That Triples Alzheimer’s Risk
The connection between TREM2 and Alzheimer’s disease became impossible to ignore in 2013, when two landmark genetic studies published in the same issue of the New England Journal of Medicine identified a rare variant called R47H. In a large Icelandic cohort, people carrying this single amino acid change in TREM2 had roughly three times the odds of developing Alzheimer’s compared to non-carriers.4PubMed Central. Variant of TREM2 associated with the risk of Alzheimer’s disease The companion study confirmed the same variant showed a strong association across multiple populations.5PubMed Central. TREM2 Variants in Alzheimer’s Disease Before these papers, only the APOE4 variant was widely recognized as a common genetic risk factor for late-onset Alzheimer’s. TREM2-R47H has a much smaller carrier frequency, but for those who carry it, the effect size is substantial.
Why does this mutation matter mechanistically? The R47H substitution sits in the ligand-binding domain of TREM2, the part that touches the outside world. Experiments showed that R47H considerably reduces TREM2’s ability to detect the lipid signals it normally senses, including phosphatidic acid, phosphatidylglycerol, phosphatidylserine, and sulfatides.1Cell. TREM2 Sustains Microglial Response to Amyloid Plaques and Damaged Neurons in Alzheimer’s Disease In effect, microglia carrying R47H have a dulled sensor: they are less able to detect the distress signals coming from amyloid plaques and damaged neurons. Single-cell RNA sequencing in mice engineered with the R47H variant confirmed that multiple microglial activation pathways were underrepresented compared to mice with normal TREM2, suggesting that TREM2 ligand engagement is required for microglia to mount a proper response.6PubMed Central. Prior activation state shapes the microglia response to antihuman TREM2 in a mouse model of Alzheimer’s disease Human studies echoed this: carriers of R47H and another variant, R62H, showed a less reactive microglial phenotype than non-carriers.7Nature Medicine. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease
How TREM2 Shapes the Microglial Response to Plaques
Microglia near amyloid plaques do not just switch from “off” to “on.” Research has revealed a two-step activation process. In the first stage, which does not require TREM2, microglia downregulate their normal housekeeping genes and begin expressing a set of early response markers. In the second stage, which is entirely TREM2-dependent, these partially activated cells upregulate genes involved in phagocytosis and lipid metabolism and fully transition into what researchers call disease-associated microglia, or DAM. When TREM2 is knocked out in mouse models, microglia get stuck at the halfway point and never complete their transformation.8Cell. Microglia and Macrophages Associated with Alzheimer’s Disease and Other Neurodegenerative Diseases – Section: DAM Activation Is Initiated by a Trem2-Independent Mechanism The downstream signaling that fuels this second stage depends on SYK: when SYK is absent, the energy- and growth-related pathways that DAM need to sustain themselves collapse, and the cells instead start cannibalizing their own components through autophagy.2Cell. Microglial SYK-mediated signaling sustains the mechanism of Alzheimer’s disease-associated microglia
One of the more striking jobs of TREM2-activated microglia is physical plaque management. In both mice and human brain tissue, microglia extend specialized protrusions rich in TREM2 and DAP12 that tightly wrap around the surface of amyloid plaques, effectively forming a barrier between the plaque and the surrounding brain tissue. When TREM2 function is reduced by even half, microglia fail to polarize toward plaques properly. The plaques themselves become less compact and spread over a larger area of brain tissue, which correlates with significantly more damage to nearby nerve fibers.9PubMed Central. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy The issue was not that fewer plaques formed; it was that the existing plaques were less contained and more toxic to their surroundings. TREM2 does not appear to prevent plaques from forming so much as it helps the brain limit the collateral damage plaques cause.
The relationship between TREM2 and tau, the other hallmark protein of Alzheimer’s, is less settled. Evidence suggests TREM2’s effect on tau pathology may differ depending on the disease stage, complicating any simple narrative about whether activating TREM2 is universally beneficial throughout the course of the disease.10PubMed Central. The role of TREM2 in Alzheimer’s disease: from the perspective of Tau
TREM2 on Tumor-Associated Macrophages
In most solid tumors, TREM2 plays a very different game. Tumors recruit macrophages from the bloodstream and reshape them into allies, creating what are called tumor-associated macrophages, or TAMs. Across many cancer types and mouse tumor models, these TAMs accumulate high levels of TREM2 on their surface.11PubMed Central. Exploring the Impact of TREM2 in Tumor-Associated Macrophages The presence of TREM2-positive TAMs is consistently linked to exhausted CD8+ T cells, the immune cells that would otherwise attack the tumor.12PubMed. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy
How does this happen? TREM2-expressing TAMs adopt an immunosuppressive profile, pumping out anti-inflammatory signals and pushing T cells toward dysfunction. In non-small cell lung cancer, for instance, TREM2-positive TAMs were enriched with anti-inflammatory cytokines and actively promoted the differentiation of regulatory T cells, which dampen the immune response, while impairing the killing capacity of CD8+ T cells.13PubMed Central. Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer The same PI3K-AKT-mTOR signaling cascade that powers beneficial microglial activation in Alzheimer’s appears to sustain these immunosuppressive macrophages inside tumors, helping them survive the nutrient-poor environment and maintain their tumor-protective functions.
This is the core of the TREM2 paradox: the signaling machinery is the same, but the context changes everything. In the brain, TREM2-driven macrophage activation cleans up disease. In a tumor, the same activation program shields cancer from immune destruction.
Blocking TREM2 to Unleash Anti-Tumor Immunity
Given that TREM2-positive TAMs suppress anti-tumor immunity, researchers have tested what happens when you block the receptor. In mouse models, deleting TREM2 genetically or treating with an anti-TREM2 antibody remodeled the tumor’s immune landscape. The immunosuppressive macrophage populations shrank, replaced by myeloid cells expressing molecules that stimulate rather than suppress T cell responses.14PubMed Central. TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy Anti-TREM2 antibody treatment alone slowed tumor growth but did not eliminate it. The more dramatic results came when anti-TREM2 was combined with anti-PD-1 checkpoint immunotherapy: in one set of experiments, the combination achieved complete tumor control in all mice tested.14PubMed Central. TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy A separate study using an Fc-enhanced anti-TREM2 antibody found a similar pattern: neither anti-PD-1 nor anti-TREM2 did much alone, but the combination produced pronounced tumor control.12PubMed. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy
These findings suggest anti-TREM2 therapy could work as a sensitizer, making tumors that resist checkpoint immunotherapy responsive again. The work is still in mouse models, but it has generated considerable excitement in immuno-oncology precisely because overcoming checkpoint resistance remains one of the field’s biggest unsolved problems.
Glioblastoma Breaks the Pattern
Just as the picture seemed to be coming together, brain tumors threw a wrench into it. Glioblastoma, the most aggressive primary brain cancer, exists in the same tissue environment as Alzheimer’s disease. And in glioblastoma, TREM2 appears to be protective against tumor progression rather than supportive of it. Research published in Cancer Cell found that TREM2 drives macrophages in the brain tumor microenvironment toward a tumor-suppressive state, the opposite of what happens in lung, breast, and colon cancers.15Cancer Cell. TREM2 is immunoprotective in glioblastoma and drives tumor-suppressive macrophage polarization
This finding complicates any plan to broadly block TREM2 as a cancer therapy. If TREM2 suppression helps fight peripheral tumors but makes brain tumors worse, the tissue context matters enormously. It also raises the question of whether the unique biology of microglia, which are a very different cell type from blood-derived macrophages despite sharing many surface markers, accounts for this reversal. For now, the glioblastoma exception serves as a stark reminder that TREM2’s function cannot be reduced to a simple “good in the brain, bad in tumors” narrative.
Therapeutic Strategies Pulling in Opposite Directions
For Alzheimer’s disease, the therapeutic logic runs toward boosting TREM2. If the R47H mutation teaches us that less TREM2 function means more disease risk, then enhancing TREM2 signaling should help microglia do their cleanup work more effectively. A humanized TREM2 agonist antibody called AL002 reached phase 2 clinical testing, a randomized, double-blind, placebo-controlled trial enrolling 381 participants with early Alzheimer’s disease.16PubMed. The TREM2 agonistic antibody AL002 in early Alzheimer’s disease: a phase 2 randomized trial The trial, known as INVOKE-2, brought both hope and sobering lessons about how difficult it is to translate microglial biology into clinical benefit.17PubMed Central. The potential and challenges of TREM2-targeted therapy in Alzheimer’s disease: insights from the INVOKE-2 study
Beyond antibodies, researchers are exploring small-molecule approaches. A compound called As48 represents a first-in-class dual-function TREM2 modulator: it both activates the receptor and prevents its shedding by ADAM proteases. Rather than directly blocking the enzymes that clip TREM2 off the cell surface, As48 appears to change the shape of the TREM2 protein near the cleavage site so the enzymes can no longer access it.18Biomedicine & Pharmacotherapy. As48, a first-in-class dual-function TREM2 modulator: Receptor activation and shedding inhibition If this mechanism holds up in further testing, it could address two problems at once: keeping more functional TREM2 on microglia while also stimulating its signaling.
For cancer, the strategy is the reverse. As described earlier, anti-TREM2 blocking antibodies aim to dismantle the immunosuppressive macrophage shield around tumors. A recent review framed this tension explicitly: TREM2 activation supports microglial function in Alzheimer’s, while its inhibition may counteract immunosuppressive macrophages in cancer.19PubMed Central. TREM2 and LAG-3 in cancer and Alzheimer’s disease immunotherapy This means any systemic therapy targeting TREM2 must grapple with the possibility that what helps one condition could worsen the other, a real concern in elderly patients who are statistically more likely to face both neurodegenerative and oncologic diagnoses.
Soluble TREM2 as a Window into Neuroinflammation
The fragment of TREM2 that gets shed from the cell surface, sTREM2, has attracted attention as a biomarker. It can be measured in cerebrospinal fluid, and elevated levels have emerged as a marker of microglial activation and neuroinflammation in Alzheimer’s disease.20PubMed Central. Biological correlates of elevated soluble TREM2 in cerebrospinal fluid Unlike amyloid and tau, which reflect the accumulation of specific pathological proteins, sTREM2 offers a read on the immune system’s activity in the brain. This is useful for clinical trials testing TREM2-targeted therapies, because it provides a way to check whether a drug is actually engaging the biology it is designed to influence. It also adds to the toolkit for staging disease, though its role in routine clinical diagnosis is still being worked out.
TREM2 in Bone Disease and Metabolism
TREM2 was actually known in bone biology before it was famous in neuroscience. The clearest illustration comes from Nasu-Hakola disease, a rare inherited condition caused by loss-of-function mutations in either TREM2 or the gene encoding its partner DAP12. People with this disease develop bone cysts that lead to fractures, along with early-onset dementia that typically appears in their thirties or forties.21PubMed Central. The TREM2-DAP12 signaling pathway in Nasu-Hakola disease: a molecular genetics perspective The combination of bone and brain pathology in one genetic condition was, in retrospect, an early clue that TREM2 operates across multiple tissue environments through the same core signaling machinery.
In mice, TREM2 deficiency causes an osteopenic phenotype, meaning low bone density, that resembles Nasu-Hakola disease. The underlying mechanism involves osteoclasts, the cells responsible for breaking down old bone. Without TREM2, osteoclast precursors fail to proliferate normally and instead rush into premature differentiation, producing excessive bone resorption.22PubMed Central. TREM2 and β-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis In the context of periodontitis, the inflammatory gum disease that destroys the bone supporting teeth, TREM2 drives a separate osteoclast mechanism involving reactive oxygen species amplification through the same DAP12-SYK cascade. Conditionally knocking out TREM2 in osteoclasts reduced the bone destruction caused by periodontitis in mice.23PubMed Central. Trem2 mediated Syk-dependent ROS amplification is essential for osteoclastogenesis in periodontitis microenvironment So even within bone biology, TREM2 can be either helpful or harmful depending on the specific disease context: its absence causes pathological bone loss in Nasu-Hakola disease, but its presence drives pathological bone destruction in periodontitis.
Lipid-Associated Macrophages and Metabolic Disease
Perhaps the most unexpected chapter in the TREM2 story involves metabolism. Researchers discovered a population of TREM2-expressing macrophages in adipose tissue, dubbed lipid-associated macrophages, or LAMs. These cells are conserved across species and appear to be part of the body’s response to disrupted fat metabolism. When TREM2 was knocked out in mice, the entire LAM program collapsed. The consequences were systemic: animals developed enlarged fat cells, high cholesterol, excess body fat, and glucose intolerance.24Cell. Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent Manner These findings position TREM2 as a broad lipid-sensing mechanism that macrophages use to maintain tissue health not just in the brain but throughout the body. They also raise questions about whether the metabolic disturbances seen in Alzheimer’s patients, who often have altered lipid profiles, might partly involve dysfunctional TREM2 signaling in peripheral tissues as well as in the brain.
The common thread across all these settings is lipid sensing. Whether TREM2 is detecting the lipids coating an amyloid plaque, the phosphatidylserine on a dying neuron, the debris from bone turnover, or the excess lipids spilling from overstuffed fat cells, it is doing fundamentally the same molecular job: telling macrophages that something in their local tissue environment needs attention. What the macrophage then does with that information depends on which tissue it lives in, what other signals are present, and whether the context is degenerative, inflammatory, or malignant. That single receptor, reading the same basic class of signals, can produce outcomes as different as neuroprotection and tumor immune evasion, which is exactly why targeting it demands careful, context-specific strategies rather than a one-size-fits-all approach.